Keiji Miyata Selected Research

YM-254890

5/2006	Biological properties of a specific Galpha q/11 inhibitor, YM-254890, on platelet functions and thrombus formation under high-shear stress.
4/2006	Effect of YM-254890, a specific Galphaq/11 inhibitor, on experimental peripheral arterial disease in rats.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Keiji Miyata Research Topics

Disease

7	Overactive Urinary Bladder (Overactive Bladder) 01/2010 - 08/2002
6	Neoplasms (Cancer) 04/2020 - 02/2002
3	Irritable Bowel Syndrome (Syndrome, Irritable Bowel) 05/2009 - 08/2006
3	Body Weight (Weight, Body) 01/2005 - 02/2002
2	Chronic Obstructive Pulmonary Disease (COPD) 01/2012 - 05/2011
2	Inflammation (Inflammations) 01/2012 - 11/2011
2	Colitis 11/2011 - 01/2011
2	Cardiovascular Diseases (Cardiovascular Disease) 01/2011 - 05/2003
2	Hypertension (High Blood Pressure) 01/2011 - 02/2004
2	Diarrhea 05/2009 - 02/2008
2	Hyponatremia 01/2009 - 01/2007
2	Arthritis (Polyarthritis) 01/2008 - 04/2005
2	Experimental Arthritis 01/2008 - 04/2005
2	Urge Urinary Incontinence (Urge Incontinence) 05/2007 - 01/2007
2	Urinary Bladder Neck Obstruction (Bladder Neck Obstruction) 09/2006 - 03/2006
2	Lower Urinary Tract Symptoms 09/2006 - 08/2004
2	Thrombosis (Thrombus) 05/2006 - 12/2004
2	Pulmonary Hypertension 06/2005 - 08/2004
2	Right Ventricular Hypertrophy 06/2005 - 08/2004
2	Hypoxia (Hypoxemia) 06/2005 - 08/2004
2	Pain (Aches) 11/2004 - 05/2004
2	Cancer Pain 11/2004 - 05/2004
2	Melanoma (Melanoma, Malignant) 11/2004 - 09/2004
2	Prostatic Neoplasms (Prostate Cancer) 11/2004 - 05/2004
2	Severe Combined Immunodeficiency (Bare Lymphocyte Syndrome) 11/2004 - 05/2004
2	Cerebral Hemorrhage 05/2003 - 04/2003
2	Hematoma 05/2003 - 04/2003
2	Thrombocytopenia (Thrombopenia) 02/2002 - 01/2002
1	Pneumonia (Pneumonitis) 01/2012
1	Lung Injury 05/2011
1	Essential Hypertension 01/2011
1	Hypoglycemia (Reactive Hypoglycemia) 11/2009
1	Glucose Intolerance 11/2009
1	Osteoporosis 01/2009
1	Seizures (Absence Seizure) 01/2009
1	Prostatic Hyperplasia (Benign Prostatic Hyperplasia) 02/2008

Drug/Important Bio-Agent (IBA)

8	N- (6- methoxy- 5- (2- methoxyphenoxy)- 2- (pyrimidin- 2- yl)pyrimidin- 4- yl)- 2- phenylethenesulfonamide (YM598)IBA 02/2008 - 02/2004
6	Solifenacin Succinate FDA Link 01/2010 - 08/2002
6	Endothelins (Endothelin)IBA 02/2008 - 05/2004
5	Muscarinic AntagonistsIBA 01/2010 - 08/2002
5	Pharmaceutical PreparationsIBA 01/2009 - 08/2002
3	Vasopressin Receptors (Arginine Vasopressin Receptor)IBA 01/2009 - 01/2005
3	conivaptan (Vaprisol)FDA Link 01/2009 - 01/2005
3	Celecoxib (Celebrex)FDA Link 01/2008 - 01/2005
3	Muscarinic Receptors (Muscarinic Acetylcholine Receptor)IBA 01/2007 - 01/2004
3	Tamsulosin (Flomax)FDA LinkGeneric 09/2006 - 08/2004
3	Bosentan (Tracleer)FDA Link 11/2004 - 08/2004
3	oxybutynin (Tavor)FDA LinkGeneric 05/2004 - 08/2002
2	Coloring Agents (Dyes)IBA 04/2020 - 09/2003
2	Dihydrotachysterol (AT 10)IBA 01/2012 - 12/2004
2	Prednisolone (Predate)FDA LinkGeneric 01/2012 - 11/2011
2	LipopolysaccharidesIBA 01/2012 - 01/2005
2	3- (4- (3- chlorophenyl)- 1- ethyl- 7- methyl- 2- oxo- 1,2- dihydro- 1,8- naphthyridin- 3- yl)propanoic acidIBA 01/2012 - 05/2011
2	Tacrolimus (Prograf)FDA LinkGeneric 11/2011 - 01/2011
2	Therapeutic UsesIBA 11/2011 - 08/2004
2	InterferonsIBA 01/2011 - 12/2002
2	ramosetron (Nasea)IBA 05/2009 - 02/2008
2	SodiumIBA 01/2009 - 01/2007
2	ElectrolytesIBA 01/2009 - 01/2007
2	Arginine Vasopressin (Argipressin)IBA 01/2009 - 01/2007
2	Mineral Oil (Liquid Paraffin)FDA LinkGeneric 01/2008 - 04/2005
2	Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA 01/2008 - 04/2005
2	Vasopressins (Vasopressin)IBA 01/2007 - 01/2005
2	YM-254890IBA 05/2006 - 04/2006
2	salicylhydroxamic acid (SHAM)IBA 01/2005 - 05/2004
2	AtrasentanIBA 11/2004 - 09/2004
2	SaltsIBA 09/2004 - 05/2004
2	darifenacin FDA Link 05/2004 - 01/2004
2	Tolterodine Tartrate (Detrol)FDA Link 05/2004 - 01/2004
2	Collagenases (Collagenase)FDA Link 05/2003 - 04/2003
2	Heparin (Liquaemin)FDA LinkGeneric 05/2003 - 04/2003
2	AMPA Receptors (AMPA Receptor)IBA 04/2003 - 01/2003
2	YM 872IBA 04/2003 - 01/2003
2	Interleukin-11 (Interleukin 11)IBA 02/2002 - 01/2002
1	MicellesIBA 04/2020
1	Indocyanine Green (Cardio-Green)FDA LinkGeneric 04/2020
1	CilomilastIBA 01/2012
1	RoflumilastIBA 01/2012
1	GlucocorticoidsIBA 11/2011
1	Phosphodiesterase 4 InhibitorsIBA 05/2011
1	SmokeIBA 05/2011
1	Telmisartan (Micardis)FDA Link 01/2011
1	Calcineurin InhibitorsIBA 01/2011
1	Drinking WaterIBA 01/2011
1	SolutionsIBA 01/2011
1	Dextran SulfateIBA 01/2011
1	SurvivinIBA 10/2010
1	sepantroniumIBA 10/2010
1	Gliclazide (Diamicron)IBA 11/2009
1	Blood Glucose (Blood Sugar)IBA 11/2009
1	4- fluoro- 1- (((4- methyl- 1- (methylsulfonyl)piperidin- 4- yl)amino)acetyl)pyrrolidine- 2- carbonitrileIBA 11/2009
1	YM 529IBA 01/2009
1	TrimebutineIBA 02/2008
1	Serotonin (5 Hydroxytryptamine)IBA 02/2008
1	Parasympatholytics (Antispasmodics)IBA 02/2008
1	Loperamide (Imodium)FDA LinkGeneric 02/2008

Therapy/Procedure

5	Therapeutics 10/2010 - 01/2002
3	Drug Therapy (Chemotherapy) 08/2002 - 01/2002
2	Intravenous Administration 01/2007 - 01/2005
2	Oral Administration 06/2005 - 11/2004